WO2003017774A1 - Composition a forte teneur lipidique au gout agreable - Google Patents
Composition a forte teneur lipidique au gout agreable Download PDFInfo
- Publication number
- WO2003017774A1 WO2003017774A1 PCT/GB2002/003864 GB0203864W WO03017774A1 WO 2003017774 A1 WO2003017774 A1 WO 2003017774A1 GB 0203864 W GB0203864 W GB 0203864W WO 03017774 A1 WO03017774 A1 WO 03017774A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- composition
- triglyceride
- emulsifier
- fat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 110
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000003995 emulsifying agent Substances 0.000 claims description 32
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 27
- 229930195729 fatty acid Natural products 0.000 claims description 26
- 239000000194 fatty acid Substances 0.000 claims description 26
- 150000004665 fatty acids Chemical class 0.000 claims description 26
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 22
- 239000000796 flavoring agent Substances 0.000 claims description 15
- 235000013355 food flavoring agent Nutrition 0.000 claims description 12
- 235000003599 food sweetener Nutrition 0.000 claims description 9
- 125000005456 glyceride group Chemical group 0.000 claims description 9
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 9
- 239000003765 sweetening agent Substances 0.000 claims description 9
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000003125 aqueous solvent Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 5
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 4
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 239000008151 electrolyte solution Substances 0.000 claims description 2
- 235000019204 saccharin Nutrition 0.000 claims description 2
- 229940081974 saccharin Drugs 0.000 claims description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 2
- 238000010792 warming Methods 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 244000240602 cacao Species 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 235000005911 diet Nutrition 0.000 abstract description 10
- 230000000378 dietary effect Effects 0.000 abstract description 8
- 235000015872 dietary supplement Nutrition 0.000 abstract description 8
- 239000002960 lipid emulsion Substances 0.000 abstract description 8
- 239000003925 fat Substances 0.000 description 46
- 235000019197 fats Nutrition 0.000 description 46
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 150000003626 triacylglycerols Chemical class 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 244000299461 Theobroma cacao Species 0.000 description 7
- 235000003441 saturated fatty acids Nutrition 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 235000021314 Palmitic acid Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 235000021313 oleic acid Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000019485 Safflower oil Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 235000021085 polyunsaturated fats Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000003813 safflower oil Substances 0.000 description 4
- 235000005713 safflower oil Nutrition 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000013367 dietary fats Nutrition 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000006014 omega-3 oil Substances 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 235000021003 saturated fats Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010016260 Fatty acid deficiency Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019625 fat content Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229940101578 microlipid Drugs 0.000 description 2
- 235000021084 monounsaturated fats Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 241001441571 Hiodontidae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000014554 bottled still water Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008370 chocolate flavor Substances 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/01—Other fatty acid esters, e.g. phosphatides
- A23D7/011—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/80—Emulsions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
Definitions
- the invention relates to a palatable orally-ingestible composition containing a high proportion of fat, which thus provides an easy way in which to provide energy in this form, and to methods of making such a composition.
- the compositions of the invention may contain a variety of different sources of fat.
- the invention may be used as a dietary supplement to provide a concentrated source of fat, or as a fat emulsion for special dietary use.
- Fat like protein and carbohydrate, is a principal and essential component of the diet. At nine kilocalories per gram, fat is the most concentrated source of energy in the diet; protein and carbohydrates contribute only about four kilocalories per gram.
- dietary fats are a source of fatty acids, including essential fatty acids that are necessary to assure the maintenance of good health. These fatty acids must be obtained from dietary sources (primarily vegetable oils), since the body cannot synthesize them itself. Fat is also responsible for transporting the fat-soluble vitamins A, D, E and K.
- Fatty acids are classified by their structure as either saturated, monounsaturated or polyunsaturated.
- Saturated fats are mainly found in foods of animal origin, including the fats in whole milk, cream, cheese, butter, meat and poultry. Saturated fats also can be found in large amounts in some vegetable products, such as cocoa butter, coconut oil and palm oil.
- Monounsaturated fats are found primarily in plants, but also are found in animals. Olive, peanut and canola oil are common examples of fats that are high in monounsaturated fatty acids.
- Polyunsaturated fats are found mostly in plants. Sunflower, corn, soybean, cotton seed and safflower oils are vegetable fats that contain a relatively high proportion of polyunsaturated fats.
- lipid emulsions that contain long chain triglycerides (LCT emulsions) that are delivered parenterally.
- LCT emulsions lipid emulsions that contain long chain triglycerides
- Parenteral delivery requires a degree of technical support (so increasing the burden on health services) and generally prevents such patients being treated at home.
- Certain pathological conditions, such as anaemia, also require a patient to intake supplemental dietary fat.
- a composition termed Calogen (SHS) is an emulsion consisting of long chain triglycerides (LCT) from highly refined peanut oil. This composition may be used as a dietary supplement to provide a concentrated source of fat in the form of long chain triglycerides. However, this composition is limited to the delivery of peanut oil and does not allow the delivery of any kind of specific triglyceride.
- a second composition, termed Microlipid® is a 50% fat emulsion for special dietary use in oral or tube-feeding formulas, that may be mixed into enteral formulas, beverages, and table food. This composition includes safflower oil (a rich source of polyunsaturated fats). Again, the technology used to produce Microlipid® does not allow the generation of a composition that can be adjusted for different fat contents.
- a palatable ingestible composition for the oral delivery of fat, said composition comprising a) a triglyceride component in a proportion of at least about 20% w/w; b) an emulsifier component consisting of a partial glyceride; c) a flavouring agent; and d) an aqueous solvent.
- compositions of the invention are palatable, meaning that the invention does not suffer the drawbacks of currently available fat compositions. There is no product currently available that provides a composition with fat as the major energy source and which focuses on the composition of the fat. Furthermore, the compositions of the invention may be modified so as to incorporate any type of triglyceride.
- triglyceride is used herein to refer to fats that may be used in the compositions of the invention.
- saturated fatty acids are very hard to emulsify and are therefore difficult to incorporate into a composition in high proportions.
- the compositions of the invention may be designed so as to emulsify saturated fatty acids in high proportions (up to 50% and above).
- compositions of the invention inco ⁇ orate high proportions of triglyceride.
- the proportion of triglyceride in the compositions according to the invention may be greater than 20% w/w, preferably, greater than 30%, more preferably, greater than 40%, even more preferably, 45%, most preferably, 50% or more.
- Suitable triglycerides may be composed of saturated fatty acids (for example, myristic acid, palmitic acid and stearic acid), monounsaturated fatty acids (for example, palmitoleic acid and oleic acid), polyunsaturated fatty acids (for example, linoleic acid, linolenic acid, arachidonic acid and n-3 polyunsaturated acids), trans-unsaturated fatty acids, omega-3 fatty acids, trans fatty acids, or a mixture of one or more of these triglycerides.
- saturated fatty acids for example, myristic acid, palmitic acid and stearic acid
- monounsaturated fatty acids for example, palmitoleic acid and oleic acid
- polyunsaturated fatty acids for example, linoleic acid, linolenic acid, arachidonic acid and n-3 polyunsaturated acids
- trans-unsaturated fatty acids omega-3 fatty acids, trans
- the invention is of particular utility with respect to the use of high proportions of saturated fatty acids, such as palmitic and stearic acids, which are very difficult to emulsify and are thus very difficult to administer in high quantities.
- saturated fatty acids such as palmitic and stearic acids
- Such triglycerides cannot presently be delivered parenterally or orally.
- an emulsifier component In order to emulsify the triglyceride into a homogenous emulsion, an emulsifier component must be included in the composition of the invention.
- the emulsifier component should include a partial glyceride or combination of partial glycerides. This component has been found to be particularly effective in emulsifying triglycerides, particularly those composed of saturated fatty acids, in a high percentage proportion into aqueous solution.
- the partial glyceride should be a monoglyceride or diglyceride or derivative thereof.
- a suitable source of partial glyceride is cocoa powder, which, in addition to protein and carbohydrate, contains a number of species of partial glyceride.
- a partial glyceride emulsifying agent known as HYMONO 8903K emulsifier (Quest International) has been found by the inventors to be particularly suitable for use in preparing compositions according to the invention.
- the emulsifier component should be present in the compositions of the invention in an amount sufficient to emulsify the amount of triglyceride that is intended to be used in the composition.
- the emulsifier component is more costly than the other components of the compositions of the invention, meaning that its use should ideally be restricted to the minimum amount that is necessary to emulsify the triglyceride.
- the proportion of emulsifier used will also vary dependent on the efficacy of the emulsifier used.
- the proportion of the emulsifier component should be between 0.1 % and 5% w/w.
- a composition according to the invention contains between 0.5% and 1 % emulsifier, more preferably, around 0.5%.
- compositions of the invention should also contain a flavouring agent.
- a flavouring agent increases the palatability of the composition, so facilitating its ingestion and imparting a pleasant taste to the composition.
- the compositions of the invention taste rather pleasant, in contrast to high fat compositions that have been prepared previously, which induce nausea and even vomiting.
- cocoa powder has a potent activity as an emulsifier, and at the same time imparts a pleasant flavour. Cocoa powder is thus an example of a preferred flavouring agent according to the invention.
- the choice of flavouring agent may differ depending on the individual or the organism for which the composition is intended.
- the flavouring agent may not be a sweetener, but may impart a savoury taste (such as fish oil for cats, or meat flavour for dogs).
- a savoury taste such as fish oil for cats, or meat flavour for dogs.
- sweeteners will generally be a component of the preferred flavouring agent, optionally in combination with cocoa powder, for example, to impart a chocolate flavour to the composition.
- sweeteners include Hermesetas granulated sweetener, saccharin and aspartame. Other examples will be clear to those of skill in the art.
- the final ingredient of the compositions according to the invention is the solvent, which should be an aqueous solvent.
- Suitable aqueous solvents include water, an aqueous electrolyte solution or an aqueous-alcoholic solvent.
- the solvent used is water.
- the compositions of the invention may be used in a number of different ways.
- the compositions may be used as dietary supplements to provide energy in the form of fat.
- this strategy is very different from the cunent goals of most food manufacturers, who, in view of the weight conscious public to whom they sell, aim to reduce the fat content of their products as much as possible.
- compositions of the invention may be sold as nutritional supplements, particularly for individuals who participate in active or endurance sports, or those participating in expeditions, such as polar expeditions, or polar research.
- Some endurance athletes may need to consume 4,000-6,000 kilocalories/day to maintain energy balance, particularly in long distance events such as ultra-marathons, long distance bicycle rides such as the Tour de France and adventure races. Daily fat consumption makes a significant contribution in meeting these energy needs.
- evidence has shown that increasing energy intake after exercise, while the athlete is resting, facilitates recovery and is likely to improve repeat performances that must be attempted within a short period of time. This is particularly important in endurance events that continue over a number of days (Saris W.H.M., Limits of human endurance: lessons from the Tour de France.
- compositions of the invention allow such a significant fat intake without requiring the ingestion of a large amount of food. Ingesting small amounts of concentrated fat in this manner may also enhance the amount of triglyceride stored and increase the rate of its storage.
- compositions of the invention might be used to enhance the fat uptake of particular animal populations, such as domesticated livestock intended for human consumption. It may be that the flavour of the animal meat or its fatty acid composition may be altered beneficially, or that the weight or growth rate of the animal may be increased in order to reduce the cost of raising livestock.
- This aspect of the invention thus provides a method for enhancing the fat uptake of an animal comprising administering to the animal a palatable ingestible composition according to any one of the embodiments of the invention described above.
- compositions of the invention may also be used as a dietary source to deliver specific fatty acids to an individual. This may be useful to address specific deficiencies suffered by individuals. For instance, essential fatty acid deficiency has been suggested to underlie attention-deficit/ hyperactivity disorder (Stevens et al, 1995, Am J Clin Nutr: 62: 761 -8) and dyslexia; pre-term infants deprived of vital fatty acids during late pregnancy are likely to have failures of normal development, especially development of the visual system, if not provided with dietary supplements of omega-3 fatty acids (Innis, 1992, Lipids, 27(1 1 ): 879-887); higher palmitic and lower omega-3 fatty acids in serum are correlated with higher incidence of coronary heart disease in middle-aged men at high risk for cardiovascular disease (Simon et al, 1995, Stroke, 26: 778-82); changes in dietary fatty acid intake cause alterations in immune response, including anti-tumor activity (Erikson et al, 1995, J
- compositions of the invention as a dietary source may also maximize the nutritional value that the compositions may provide.
- This aspect of the invention thus provides a method for treating a disorder relating to a fatty acid deficiency in a patient, said method comprising administering to the patient a palatable ingestible composition according to any one of the embodiments of the invention described above.
- the compositions of the invention may also be used as tools for human and animal research to increase specific fatty acids in the circulation and to test for the effect of this manipulation on physiology. In this manner, the effects of particular fatty acids on metabolism may be assessed, not only for healthy individuals, but also for individuals who are severely overweight or underweight.
- the metabolic effect of ingesting too much or too little fat, or too much or too little of a specific type of fat may be assessed and the types of fatty acid that are beneficial or detrimental to health can be evaluated rationally.
- These effects may also be evaluated for diseased individuals, such as those suffering from diabetes, and the metabolic patterns found in diseased and healthy individuals can be compared.
- the compositions of the invention allow a researcher to be able to alter the dietary intake of fats in such individuals, as desired.
- compositions of the invention have an acceptable shelf-life, in that they can be stored refrigerated or at room temperature for a significant period of time and reconstituted by brief shaking before use.
- This is a further advantage of the compositions of the present invention in that no specialized equipment or refrigeration is required to store the compositions. This means, for example, that the compositions may be sold to the public at normal grocer-type outlets and will not need to be prepared upon demand by dispensing chemists.
- compositions of the invention may also be freeze-dried.
- Granules of freeze-dried composition may then be reconstituted when required, for example, using warm water and stirring vigorously.
- Such freeze-dried or lyophilised compositions form a further aspect of the invention.
- a method of preparing a palatable ingestible composition comprising the steps of: a) combining the triglyceride and emulsifier components and warming the mixture until the emulsifier component has melted into the oil; b) adding the flavouring agent to the solution of triglyceride and emulsifier components; c) slowly mixing the solvent into the composition whilst stirring continuously; d) blending the final composition together to form an emulsion.
- the method is performed in the order of steps recited above.
- step a the triglyceride and emulsifier components are combined and the mixture is warmed, generally to around 65-70°C, when the emulsifier component will gradually melt into the oil.
- the temperature to which the mixture is raised will depend upon the type of triglyceride that is to be incorporated into the composition. For example, saturated fats are usually solid at room temperature, whilst monounsaturated fats are liquid and polyunsaturated fats are usually liquid at room temperature.
- the melting temperature may thus need to be increased above 70°C for compositions that incorporate a large amount of saturated triglyceride. The temperature should be kept well below boiling point.
- flavouring agent should then be mixed into the solution of triglyceride and emulsifier components.
- the next step is the incorporation of the aqueous solvent into the composition. This should be done very slowly, with the solution being mixed continuously while the solvent is being inco ⁇ orated. Finally, the resulting composition is blended together to form an emulsion. This may be performed using any of a number of techniques, as the skilled reader will be aware. In the case of a small-scale laboratory process, a hand-mixer may be used, homogenizing the composition for around two minutes.
- Figure 1 shows specific fatty acid composition during a test with olive oil in which small portions of the high fat emulsion are used to produce continuous absorption of the fat of interest (as triglycerides) accompanied by a slow infusion of heparin, a substance to activate the enzyme lipoprotein lipase;
- Figure 2 shows specific fatty acid composition during safflower oil test
- Figure 3 shows specific fatty acid composition during palm stearin test.
- Palm stearin (Anglia Oils Limited, King George Dock, Hull) for enrichment in palmitic acid in plasma
- Cadbury's Cocoa powder (322 kcal, 23.1 g protein, 10.5 g carbohydrates, 20.8 g fat)
- Hermesetas granulated sweetener Bottled still water
- compositions of the invention have been tested for palatability and absorption in man.
- Three different compositions have been used as research tools to increase specific fatty acids in the circulation in man. This was achieved by feeding small portions of the high fat emulsion to produce continuous abso ⁇ tion of the fat (as triglycerides) of interest accompanied by a slow infusion of heparin, a substance to activate the enzyme lipoprotein lipase. This enzyme hydrolyses the absorbed triglycerides in the circulation into smaller components, non-esterified fatty acids (NEFA).
- NEFA non-esterified fatty acids
- Figure 1 shows the increase in linoleic acid in plasma from eight volunteers when linoleic acid was the main fatty acid used in the composition.
- Figure 2 shows the increase of mainly palmitic acid in plasma when palmitic acid was the main fatty acid used in the composition.
- Figure 3 shows the increase in plasma oleic acid when oleic acid was the main fatty acid used in the composition.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0120415.5 | 2001-08-22 | ||
GBGB0120415.5A GB0120415D0 (en) | 2001-08-22 | 2001-08-22 | Palatable high fat composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003017774A1 true WO2003017774A1 (fr) | 2003-03-06 |
Family
ID=9920816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/003864 WO2003017774A1 (fr) | 2001-08-22 | 2002-08-22 | Composition a forte teneur lipidique au gout agreable |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0120415D0 (fr) |
WO (1) | WO2003017774A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063323A3 (fr) * | 2006-10-13 | 2008-12-31 | Reliant Pharmaceuticals Inc | Traitement à base d'anti-arythmisants et d'acides gras oméga-3 et produit mixte obtenu à partir de ceux-ci |
WO2011057731A1 (fr) * | 2009-11-10 | 2011-05-19 | Cognis Ip Management Gmbh | Composition comprenant un lipide approprié à la consommation humaine |
CN102264246A (zh) * | 2008-10-24 | 2011-11-30 | N.V.努特里奇亚 | 液体高脂肪蛋白组合物 |
EP2775862B1 (fr) | 2011-11-07 | 2016-09-28 | Nestec S.A. | Stabilisation d'émulsion |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3851070A (en) * | 1971-06-28 | 1974-11-26 | Procter & Gamble | High nutrition food spreads |
US4199608A (en) * | 1977-11-30 | 1980-04-22 | Scm Corporation | Low calorie containing imitation dairy products |
WO1992009209A1 (fr) * | 1990-11-23 | 1992-06-11 | Unilever N.V. | Utilisation de phases mesomorphes dans les produits alimentaires |
EP0563593A1 (fr) * | 1992-03-02 | 1993-10-06 | Kao Corporation | Emulsion type huile dans l'eau pour crème fouettée respectivement poudre de crème fouettée |
EP0609465A1 (fr) * | 1992-08-21 | 1994-08-10 | Fuji Oil Company, Limited | Creme patissiere |
-
2001
- 2001-08-22 GB GBGB0120415.5A patent/GB0120415D0/en not_active Ceased
-
2002
- 2002-08-22 WO PCT/GB2002/003864 patent/WO2003017774A1/fr not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3851070A (en) * | 1971-06-28 | 1974-11-26 | Procter & Gamble | High nutrition food spreads |
US4199608A (en) * | 1977-11-30 | 1980-04-22 | Scm Corporation | Low calorie containing imitation dairy products |
WO1992009209A1 (fr) * | 1990-11-23 | 1992-06-11 | Unilever N.V. | Utilisation de phases mesomorphes dans les produits alimentaires |
EP0563593A1 (fr) * | 1992-03-02 | 1993-10-06 | Kao Corporation | Emulsion type huile dans l'eau pour crème fouettée respectivement poudre de crème fouettée |
EP0609465A1 (fr) * | 1992-08-21 | 1994-08-10 | Fuji Oil Company, Limited | Creme patissiere |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063323A3 (fr) * | 2006-10-13 | 2008-12-31 | Reliant Pharmaceuticals Inc | Traitement à base d'anti-arythmisants et d'acides gras oméga-3 et produit mixte obtenu à partir de ceux-ci |
CN102264246A (zh) * | 2008-10-24 | 2011-11-30 | N.V.努特里奇亚 | 液体高脂肪蛋白组合物 |
WO2011057731A1 (fr) * | 2009-11-10 | 2011-05-19 | Cognis Ip Management Gmbh | Composition comprenant un lipide approprié à la consommation humaine |
EP2775862B1 (fr) | 2011-11-07 | 2016-09-28 | Nestec S.A. | Stabilisation d'émulsion |
US11006651B2 (en) | 2011-11-07 | 2021-05-18 | Societe Des Produits Nestle S.A. | Emulsion stabilization method |
US11213042B2 (en) | 2011-11-07 | 2022-01-04 | Societe Des Produits Nestle S.A. | Chocolate product with cocoa particles as the emulsifying agent |
Also Published As
Publication number | Publication date |
---|---|
GB0120415D0 (en) | 2001-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4555471B2 (ja) | ストレスにより誘発された免疫抑制を低減する製品および方法 | |
ES2478869T3 (es) | Composición nutricional enteral líquida adecuada para alimentación por sonda | |
EP0482715B1 (fr) | Composition nutritionnelle | |
CA2234398C (fr) | Composition nutritive pour diabetiques et methode d'obtention | |
US8178487B2 (en) | Method for providing glutamine | |
KR970005330B1 (ko) | 사람 면역 결핍 바이러스에 감염된 사람에 대한 영양 제품 | |
EP1662905A1 (fr) | Systeme lipidique et ses procedes d'utilisation | |
JPS6236645B2 (fr) | ||
JPH08322509A (ja) | 多様性組成物形態の栄養素供給方法 | |
WO2016010102A1 (fr) | Composition nutritionnelle | |
WO2018008715A1 (fr) | Composition alimentaire sous forme de gel et aliment utilisant ladite composition alimentaire sous forme de gel | |
CN105188411A (zh) | 增强dha和其它脂溶性营养物的生物利用度的方法 | |
JP3781157B2 (ja) | 嚥下困難者用粉末栄養組成物 | |
WO2016010101A1 (fr) | Aliment émulsifié sous forme de gel | |
EP0388237A2 (fr) | Produit diététique | |
WO2003017774A1 (fr) | Composition a forte teneur lipidique au gout agreable | |
RU2463800C2 (ru) | Сухой специализированный белково-углеводный продукт для питания спортсменов | |
JPH08169824A (ja) | 小児科脂質乳剤 | |
JP3886063B2 (ja) | 栄養組成物 | |
EA026141B1 (ru) | Инстантный функциональный пищевой продукт | |
WO2002094039A1 (fr) | Aliments ou boissons ameliorant les regimes pauvres en calories et en proteines | |
JPS61135572A (ja) | 経腸用脂肪乳剤 | |
JPH03290166A (ja) | 栄養組成物 | |
WO2001043570A1 (fr) | Composition permettant d'ameliorer la reponse proliferative durant l'adaptation du tractus gastro-intestinal et utilisation dans le cadre du syndrome de l'intestin court | |
Zarotis | Prevention of overweight and obesity through nutrition in childhood and adolescence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |